These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22064545)

  • 1. Population pharmacokinetics of voriconazole in adults.
    Hope WW
    Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
    Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.
    Han K; Bies R; Johnson H; Capitano B; Venkataramanan R
    Clin Pharmacokinet; 2011 Mar; 50(3):201-14. PubMed ID: 21294597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.
    Han K; Capitano B; Bies R; Potoski BA; Husain S; Gilbert S; Paterson DL; McCurry K; Venkataramanan R
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4424-31. PubMed ID: 20679503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2601-5. PubMed ID: 21422207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
    Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
    Liu P; Mould DR
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4718-26. PubMed ID: 24913161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
    Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole pharmacokinetics in liver transplant recipients.
    Johnson HJ; Han K; Capitano B; Blisard D; Husain S; Linden PK; Marcos A; Kwak EJ; Potoski B; Paterson DL; Romkes M; Venkataramanan R
    Antimicrob Agents Chemother; 2010 Feb; 54(2):852-9. PubMed ID: 19933807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
    Chan HM; Duran SH; Walz PH; Ravis WR
    J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.
    Boyd NK; Zoellner CL; Swancutt MA; Bhavan KP
    Antimicrob Agents Chemother; 2012 Nov; 56(11):6001-2. PubMed ID: 22890768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
    Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
    Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
    Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M
    Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
    Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
    Pascual A; Nieth V; Calandra T; Bille J; Bolay S; Decosterd LA; Buclin T; Majcherczyk PA; Sanglard D; Marchetti O
    Antimicrob Agents Chemother; 2007 Jan; 51(1):137-43. PubMed ID: 17088483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
    Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
    Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.